Yuki Kurahashi Selected Research

OR-2100

1/2022

Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuki Kurahashi Research Topics

Disease

2	Neoplasms (Cancer) 01/2022 - 01/2020
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021

Drug/Important Bio-Agent (IBA)

3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2020
1	pyrimidineIBA 01/2022
1	Imatinib Mesylate (Gleevec)FDA Link 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	EnzymesIBA 01/2022
1	OR-2100IBA 01/2022
1	MethyltransferasesIBA 01/2021

Therapy/Procedure

1	Therapeutics 01/2022